Treatment of Lipodystrophy with Troglitazone

The document discussed the treatment of lipodystrophy with troglitazone, showing that after 6 months, body fat increased by 2.4 percentage points, especially in the subcutaneous region, while the respiratory quotient decreased, indicating enhanced lipogenesis and lipid oxidation. Troglitazone significantly increased subcutaneous fat but not visceral abdominal fat, raising questions about the link between insulin resistance and fat distribution. The study involved patients with genetic lipodystrophy and found that troglitazone promoted adipogenesis. Additionally, the document covered other medical cases, including a 63-year-old woman with inclusion-body myositis treated with intravenous immunoglobulin and a 58-year-old woman with chemoresistant osseous non-Hodgkin lymphoma treated with rituximab, both showing significant improvement. It also highlighted the need for further research into immunologic reactions to the HBV vaccine.